Evaluation of Intestinal Lesions and Disease Activity in Inflammatory Bowel Disease Based on 18F-FAPI PET Imaging

Launched by DAPING HOSPITAL AND THE RESEARCH INSTITUTE OF SURGERY OF THE THIRD MILITARY MEDICAL UNIVERSITY · Apr 18, 2025

Keywords

ClinConnect Summary

This clinical trial is designed to investigate how well a special type of imaging called 18F-FAPI PET can identify problems in the intestines and measure how active inflammatory bowel disease (IBD) is. Researchers want to find out if this imaging technique is effective in spotting intestinal lesions, which are areas of damage or inflammation in the bowel. The study will involve patients undergoing 18F-FAPI PET imaging, along with other tests like colonoscopy and enhanced abdominal CT, all within the same week. Participants will be monitored for any major health issues for a year after joining the study.

To be eligible for this trial, participants need to be adults aged 18 or older who have been diagnosed with IBD through various medical evaluations. They should be willing to take part in the study and give their consent. However, pregnant or breastfeeding women, as well as those whose imaging results cannot be clearly interpreted, will not be able to participate. If you or someone you know is interested, this trial could provide valuable insights into new ways to evaluate and understand IBD.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed with IBD according to clinical, imaging, endoscopic, and histopathological criteria;
• • Patients ≥18 years old;
• • 18F-FAPI PET/CT intestinal imaging, conventional endoscopic and enhanced CT were performed within 1 week;
• • Intestinal segment matching was evaluated by endoscopy and imaging;
• • Patients voluntarily participate and sign informed consent.
• Exclusion Criteria:
• • Pregnant or lactating patients;
• • Imaging images are of poor quality and cannot be used for diagnosis and evaluation;
• • Patients with contraindications for endoscopic or CT examination.